Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287392 | 0.87 | F11 (0.52) | ADORA2AADORA1ADORA3F11PIN1 | |
| SCHEMBL6282306 | 0.85 | TRPM8 (0.57) | ADORA2AADORA1ADORA3ADORA2BRORC | |
| SCHEMBL6288670 | 0.83 | KMT2A (0.56) | ADORA2AADORA1ADORA3ADORA2BRORC | |
| SCHEMBL1967240 | 0.81 | PIN1 (0.49) | ADORA2AADORA1ADORA3F11PIN1 | |
| SCHEMBL276196 | 0.81 | NTRK1 (0.57) | RORCTRPM8 | |
| SCHEMBL1919770 | 0.79 | FNTA (0.55) | FNTAFNTBGRM5TRPM8 | |
| SCHEMBL6279541 | 0.78 | DHODH (0.55) | ADORA2AADORA1FNTAFNTB | |
| SCHEMBL6288104 | 0.78 | ALDH1A1 (0.69) | ADORA2AFNTAFNTB | |
| SCHEMBL6288115 | 0.78 | FNTA (0.54) | FNTAFNTBGRM5TRPM8 | |
| SCHEMBL1398686 | 0.76 | GAA (0.50) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962935-B2 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | PRUITT JAMES RUSSELL (US) | 2004-04-15 | — | — | US | disclosed |
| US-6569874-B1 | Such as 2-acetylamino-4-(3-amidinophenyl)-5-((2'-amino-sulfonyl-(1,1')-biphen-4 -yl)aminocarbonyl)thiazole; for treatment of thromboembolic disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0946528-B1 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6187797-B1 | ANTICOAGULANTS; TRYPSINE-LIKE SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-13 | — | — | US | disclosed |
| EP-0946528-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028282-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | F12, XDH, F2 | ADORA2A 1872/4885ADORA1 1600/4885ADORA3 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.